FDA Issues Alert on SARS-CoV-2 Viral Mutations and the Associated Impact on Testing
The U.S. Food and Drug Administration is evaluating the potential impact of SARS-CoV-2 viral mutations on authorized molecular tests.
The U.S. Food and Drug Administration is evaluating the potential impact of SARS-CoV-2 viral mutations on authorized molecular tests.
On March 24, MLMIC and HANYS will host “Beyond the Behavioral Health Unit: Managing Mental Health.” This webinar will outline strategies for meeting the mental health needs of patients in the emergency department, the general inpatient unit and the ambulatory care setting
There are key factors to consider when determining whether a telehealth encounter is the right choice for an individual patient.
Despite strain caused by the pandemic, healthcare organizations must be diligent in protecting their networks and implementing measures that secure patient data.
You have been subscribed.
There was a problem submitting the form, please reload the page and try again.